Incorporation of proteinase inhibitors into silk-based delivery devices for enhanced control of degradation and drug release

Biomaterials

Volumn 32, Issue 3, 2011, Pages 909-918

  Pritchard, Eleanor M ^a   Valentin, Thomas ^a   Boison, Detlev ^b   Kaplan, David L ^a  

^a Tufts University   (United States)

^b LEGACY RESEARCH   (United States)

Author keywords

Biodegradation; Biomaterials; Controlled drug release; Protease; Silk

Indexed keywords

BIOMATERIAL DEGRADATION; BIOMEDICAL APPLICATIONS; CONTROLLED DRUG RELEASE; DEGRADATION RATE; DELAYED RELEASE; DELIVERY DEVICE; DRUG CARRIER; DRUG RELEASE; DRUG-RELEASE RATE; ENZYMATIC FUNCTIONS; ENZYME FUNCTIONS; ETHYLENEDIAMINETETRAACETIC ACID; IN-VITRO; PROTEASE; PROTEINASE INHIBITORS; PROTEOLYTIC ACTIVITIES; SMALL MOLECULES; SUSTAINED RELEASE;

ACIDS; BIODEGRADABLE POLYMERS; BIODEGRADATION; BIOLOGICAL MATERIALS; BIOMATERIALS; DEGRADATION; DRUG DELIVERY; DRUG PRODUCTS; METAL ANALYSIS; MICROBIOLOGY; TISSUE ENGINEERING;

SILK;

ADENOSINE; ANTICONVULSIVE AGENT; EDETIC ACID; POLYMER; PROTEINASE INHIBITOR;

ARTICLE; DRUG RELEASE; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN DEGRADATION; SILK;

BIOCOMPATIBLE MATERIALS; DRUG CARRIERS; PEPTIDE HYDROLASES; SILK;

EID: 78549275747     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.09.055     Document Type: Article

References (82)

1. De Paoli Lacerda S.H., Ingber B., Rosenzweig N. Structure-release rate correlation in collagen gels containing fluorescent drug analogs. Biomaterials 2005, 26:7164-7172.
2. Langer R. Invited review: polymeric delivery systems for controlled drug release. Chem Eng Commun 1980, 6:1-48.
3. Lebovits A.H., Strain J.J., Messe M.R., Schleifer S.J., Tanaka J.S., Bhardwaj S. Patient noncompliance with self-administered chemotherapy. Cancer 1990, 65:17-22.
4. Danckwerts M., Fassih A. Implantable controlled release drug delivery systems: a review. Drug DevInd Pharm 1991, 17:1465-1502.
5. Daugherty A.L., Mrsny R.J. Formulation and delivery issues for monoclonal antibody therapeutics. Adv Drug Deliv Rev 2006, 58:686-706.
6. Sofia S., McCarthy M.B., Gronowicz G., Kaplan D.L. Functionalized silk-based biomaterials for bone formation. J Biomed Mater Res 2001, 54:139-148.
7. Tang X., Ding F., Yang Y., Hu N., Gi X. Evaluation of in vitro biocompatibility of silk fibroin-based biomaterials with primarily cultured hippocampal neurons. J Biomed Mater Res A 2009, 91A:166-174.
8. Meinel L., Hofmann S., Karageorgiou V., Kirker-Head C., McCool J., Gronowicz G., et al. The inflammatory responses of silk films in vitro and in vivo. Biomaterials 2005, 26:147-155.
9. Altman G.H., Diaz F., Jakuba C., Calabro T., Horan R.L., Chen J., et al. Silk-based biomaterials. Biomaterials 2003, 24:401-416.
10. Horan R.L., Antle K., Collette A.L., Wang Y., Huang J., Moreau J.E., et al. In vitro degradation of silk fibroin. Biomaterials 2005, 26:3385-3393.
11. Wang Y., Rudym D.D., Walsh A., Abrahamsen L., Kim H.J., Kim H.S. In vivo degradation of three-dimensional silk fibroin scaffolds. Biomaterials 2008, 29:3415-3428.
12. Numata K, Kaplan DL. Silk-based delivery systems of bioactive molecules. Adv Drug Deliv Rev 2010, in press.
13. Kim U.J., Park J., Li C., Jin H.J., Valluzzi R., Kaplan D.L. Structure and property of silk hydrogels. Biomacromolecules 2004, 5:786-792.
14. Hofmann S., Foo S.T., Rossetti F., Textor M., Vunjak-Novakovic G., Kaplan D.L. Silk fibroin as an organic polymer for controlled drug delivery. J Control Release 2006, 111:219-227.
15. Wang X., Wenk E., Matsumoto A., Meinel L., Li C., Kaplan D.L. Silk microspheres for encapsulation and controlled release. J Control Release 2007, 117:360-370.
16. Wenk E., Wandrey A.J., Merkle H.P., Meinel L. Silk fibroin spheres as a platform for controlled drug delivery. J Control Release 2008, 132:26-34.
17. Kundu J., Chung Y.-I., Kim Y.H., Tae G., Kundua S.C. Pharmaceutical nanotechnology: silk fibroin nanoparticles for cellular uptake and control release. Int J Pharm 2010, 388:242-250.
18. Lammel A.S., Hu X., Park S.-H., Kaplan D.L., Scheibel T.R. Controlling silk fibroin particle features for drug delivery. Biomaterials 2010, 31:4583-4591.
19. Wang X., Yucel T., Lu Q., Hu X., Kaplan D.L. Silk nanospheres and microspheres from silk/pva blend films for drug delivery. Biomaterials 2010, 31:1025-1035.
20. Wang X., Hu X., Daley A., Rabotyagova O., Cebe P., Kaplan D.L. Nanolayer biomaterial coatings of silk fibroin for controlled release. J Control Release 2007, 121:190-199.
21. Pritchard E.M., Szybala C., Boison D., Kaplan D.L. Silk fibroin encapsulated reservoirs for sustained release of adenosine. J Control Release 2010, 144:159-167.
22. Wilz A., Pritchard E.M., Li T., Lan J.-Q., Kaplan D.L., Boison D. Silk polymer-based adenosine release: therapeutic potential for epilepsy. Biomaterials 2008, 29:3609-3616.
23. Szybala C., Pritchard E.M., Lusardi T.A., Li T., Wilz A., Kaplan D.L., et al. Antiepileptic effects of silk-polymer based adenosine release in kindled rats. Exp Neurol 2009, 219:126-135.
24. Friess W. Collagen - biomaterial for drug delivery. Eur J Pharm Biopharm 1998, 45:113-136.
25. Young S., Wong M., Tabata Y., Mikos A.G. Gelatin as a delivery vehicle for the controlled release of bioactive molecules. J Control Release 2005, 109:256-274.
26. Luo Y., Kirker K.R., Prestwich G.D. Cross-linked hyaluronic acid hydrogel films: new biomaterials for drug delivery. J Control Release 2000, 69:169-184.
27. Kincl F.A., Ciaccio L.A. Suppression of immune responses by progesterone. Endocrinol Exp 1980, 14:27-33.
28. Friess W., Zhou W., Groves M.J. In vivo activity of collagen matrices containing PS1, an anti-neoplastic glycan, against murine sarcoma cells. Pharm Sci 1996, 2:1-4.
29. Aigner T., Stöve J. Collagens-major component of the physiological cartilage matrix, major target of cartilage degeneration, major tool in cartilage repair. Adv Drug Deliv Rev 2003, 55:1569-1593.
30. Chintala S.K., Tonn J.C., Rao J.S. Matrix metalloproteinases and their biological function in human gliomas. Int J Dev Neurosci 1999, 17:495-502.
31. Licastro F., Davis L.J., Morini M.C., Cucinotta D., Savorani G. Cerebrospinal fluid of patients with senile dementia of Alzheimer's type shows an increased inhibition of alpha-chymotrypsin. Alzheimer Dis Assoc Disord 1994, 8:241-249.
32. Kurisawa M., Chung J.E., Yang Y.Y., Gao S.J., Uyama H. Injectable biodegradable hydrogels composed of hyaluronic acid-tyramine conjugates for drug delivery and tissue engineering. Chem Commun 2005, 4312-4314.
33. Putnam D., Kopecek J. Enantioselective release of 5-fluorouracil from N-(2-hydroxypropyl)methacrylamide-based copolymers via lysosomal enzymes. J Bioconjug Chem 1995, 6:483-492.
34. Chau Y., Tan F.E., Langer R. Synthesis and characterization of dextran-peptide-methotrexate conjugates for tumor targeting via mediation by matrix metalloproteinase II and matrix metalloproteinase IX. Bioconjug Chem 2004, 15:931-941.
35. Law B., Weissleder R., Tung C.-H. Peptide-based biomaterials for protease-enhanced drug delivery. Biomacromolecules 2006, 7:1261-1265.
36. Duffy M.J. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004, 10:39-49.
37. Zolnik B.S., Burgess D.J. Effect of acidic pH on PLGA microsphere degradation and release. J Control Release 2007, 122:338-344.
38. Zolnik B.S., Leary P.E., Burgess D.J. Elevated temperature accelerated release testing of PLGA microspheres. J Control Release 2006, 112:293-300.
39. Uhrich K.E., Cannizzaro S.M., Langer R.S., Shakesheff K.M. Polymeric systems for controlled drug release. Chem Rev 1999, 99:3181-3198.
40. Schmitt E.A., Flanagan D.R., Linhardt R.J. Importance of distinct water environments in the hydrolysis of poly(DL-lactide-co-glycolide). Macromolecules 1994, 27:743-748.
41. Zhou S., Deng X., Li X., Jia W., Liu L. Synthesis and characterization of biodegradable low molecular weight aliphatic polyesters and their use in protein-delivery systems. J Appl Polym Sci 2004, 91:1848-1856.
42. Moioli E.K., Hong L., Guardado J., Clark P.A., Mao J.J. Sustained release of TGF β3 from PLGA microspheres and its effect on early osteogenic differentiation of human mesenchymal stem cells. Tissue Eng 2006, 12:537-546.
43. Ward D.R., Lathrop L.B., Lynch M.J. Dissolution and compatibility considerations for the use of mannitol in solid dosage forms. J Pharm Sci 1969, 58:1464-1467.
44. Li M., Ogiso M., Minoura N. Enzymatic degradation behavior of porous silk fibroin sheets. Biomaterials 2003, 24:357-365.
45. Lesniak M.S., Upadhyay U., Goodwin R., Tyler B., Brem H. Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res 2005, 25:3825-3831.
46. Sorensen K. An easy microtiter plate-based chromogenic assay for ethylenediamine tetraacetic acid and similar chelating agents in biochemical samples. Anal Biochem 1992, 206:210-211.
47. Ritger P.L., Peppas N.A. A simple equation for description of solute release I. Fickian and non-fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J Control Release 1987, 5:23-36.
48. Beynon R., Bond J.S. Proteolytic enzymes: a Practical approach 2001, Oxford University Press, Oxford.
49. Arai T., Freddi G., Innocenti R., Tsukada M. Biodegradation of Bombyx mori silk fibroin fibers and films. J Appl Polym Sci 2004, 91:2383-2390.
50. Yang Y., Zhao Y., Gu Y., Yan X., Liu J., Ding F., et al. Degradation behaviors of nerve guidance conduits made up of silk fibroin in vitro and in vivo. Polym Degrad Stabil 2009, 94:2213-2220.
51. Makaya K., Terada S., Ohgo K., Asakura T. Comparative study of silk fibroin porous scaffolds derived from salt/water and sucrose/hexafluoroisopropanol in cartilage formation. J Biosci Bioeng 2009, 108:68-75.
52. Park S.-H., Gil E.S., Shi H., Kim H.J., Lee K., Kaplan D.L. Relationships between degradability of silk scaffolds and osteogenesis. Biomaterials 2010, 31:6162-6172.
53. Nuanchai K., Prasong S., Wilaiwan S. In vitro degradation of Bombyx mori silk fibroin films exposed to protease XXIII. Biotechnology 2009, 8:468-472.
54. Minoura N., Tsukada M., Nagura M. Physico-chemical properties of silk fibroin membrane as a biomaterial. Biomaterials 1990, 11:430-434.
55. Jeong J., Hur W. Even-numbered peptides from a papain hydrolysate of silk fibroin. J Chromatogr 2010, B878:836-840.
56. Cao Y., Wang B. Biodegradation of silk biomaterials. Int J Mol Sci 2009, 10:1514-1524.
57. Yoshioka T., Kawazoe N., Tateishi T., Chen G. In vitro evaluation of biodegradation of poly(lactic-co-glycolic acid) sponges. Biomaterials 2008, 29:3438-3443.
58. Dorta M., Santoveña A., Llabrés M., Fariña J.B. Potential applications of PLGA film-implants in modulating in vitro drugs release. Int J Pharm 2002, 248:149-156.
59. Zhang X., McAuley K.B., Goosen M.F.A. Towards prediction of release profiles of antibiotics from coated poly (DL-lactide) cylinders. J Control Release 1995, 34:175-179.
60. Roberts M.H., Bentley M.D., Harria J.M. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 2002, 54:439-476.
61. Østergaard J., Larsen S.W., Parshad H., Larsen C. Bupivacaine salts of diflunisal and other aromatic hydroxycarboxylic acids: aqueous solubility and release characteristics from solutions and suspensions using a rotating dialysis cell model. Eur J Pharm Sci 2005, 26:280-287.
62. Patil S.D., Papadmitrakopoulos F., Burgess D.J. Concurrent delivery of dexamethasone and VEGF for localized inflammation control and angiogenesis. J Control Release 2007, 117:68-79.
63. Saltzman W.M., Olbricht W.L. Building drug delivery into tissue engineering. Nat Rev Drug Discov 2002, 1:177-186.
64. Hewitt C.W., Black K.S. Overview of a 10-year experience on methods and compositions for inducing site-specific immunosuppression with topical immunosuppressants. Transplant Proc 1996, 28:922-923.
65. Kurioka A., Yamazaki M., Hirano H. Primary structure and possible functions of a trypsin inhibitor of Bombyx mori. Eur J Biochem 1999, 259:120-126.
66. Proteolytic enzymes: Tools and Targets 1999, Springer-Verlag, New York. E.E. Sterchi, W. Stocker (Eds.).
67. Furia T. EDTA in foods- a technical review. Food Technol 1964, 18:1874-1882.
68. Ellis M.R., Kane K.Y. Lightening the lead load in children. Am Fam Physician 2000, 62:545-554.
69. Gracia R.C., Snodgrass W.R. Lead toxicity and chelation therapy. Am J Health Syst Pharm 2007, 64:45-53.
70. 2EDTA and thiamine. J Vet Diagn Invest 1995, 7:531-537.
71. Cacchio A., de Blasis E., de Siati P., Spacca G., Santilli V., de Paulis F. Effectiveness of treatment of calcific tendinitis of the shoulder by disodium EDTA. Arthritis Rheum 2009, 61:84-91.
72. Price Evans D.A., Tariq M., Sujata B., McCann G., Sobki S. The effects of magnesium sulphate and EDTA in the hypercholesterolaemic rabbit. Diabetes Obes Metab 2001, 3:417-422.
73. Maniscalco B.S., Taylor K.A. Calcification in coronary artery disease can be reversed by EDTA-tetracycline long-term chemotherapy. Pathophysiology 2004, 11:95-101.
74. Lamas G.A., Hussein S.J. EDTA chelation therapy meets evidence-based medicine. Complemen Ther Clin Pract 2006, 12:213-215.
75. Bernstein H.-G. Proteases and Alzheimer's disease: present knowledge and emerging concepts of therapy. Proteases in the brain 2005, Springer, New York. U. Lendeckel, N.M. Hooper (Eds.).
76. Wooley R.E., Jones M.S. Action of EDTA-Tris and antimicrobial agent combinations on selected pathogenic bacteria. Vet Microbiol 1983, 8:271-280.
77. Lambert R.J.W., Hanlon G.W., Denyer S.P. The synergistic effect of EDTA/antimicrobial combinations on Pseudomonas aeruginosa. J Appl Microbiol 2004, 96:244-253.
78. Ihedioha J.I., Ochiogu I.S., Ihedioha T.E. Co-administration of Na-EDTA and Diminazene Aceturate (DA). J Comp Pathol 2007, 136:206-211.
79. Girish K.S., Kemparaju K. Inhibition of Naja naja venom hyaluronidase: role in the management of poisonous bite. Life Sci 2006, 78:1433-1440.
80. 2EDTA. Am J Trop Med Hyg 2000, 63:313-319.
81. Burrell M.M. Enzymes of molecular Biology 1994, Humana Press, Totowa, pp. 271-276.
82. Numata K, Kaplan DL. Mechanisms of enzymatic degradation of amyloid β microfibrils generating nanofilaments and nanospheres related to cytotoxicity. Biochemistry 2010, in press.